We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Daniel Berman MD

Daniel S Berman MD

Professor, Departments of Imaging and Cardiology, Cedars-Sinai Medical Center; Director, Cardiac Imaging, Cedars-Sinai Heart Institute, Los Angeles, California

Dr. Berman has been head of nuclear cardiology at Cedars-Sinai Medical Center for over 30 years and a professor of medicine at the UCLA David Geffen School of Medicine since 1986. His career has been largely devoted to developing and optimizing the methods for acquiring, processing, quantifying and reporting single photon emission computer tomography (SPECT) and more recently positron emission tomography (PET) MPI, developing the acquisition and processing protocols, standardizing these assessments across laboratories, and reporting evidence regarding the ways in which these methods are useful for risk assessment and guiding patient management decisions. He was an author of the original ASNC guidelines for the performance and interpretation of SPECT MPI.

Dr. Berman has been the medical director of the Artificial Intelligence in Medicine program at Cedars-Sinai which developed and validated the quantitative assessment methods that are used in the core laboratory. He has developed and directed the Cedars-Sinai Nuclear Cardiology Database, which has prospectively recorded over 400 historical, clinical, stress testing, and nuclear variables obtained with rest/stress MPI at the time of testing and follow-up information in over 22,000 unique patients.  Using this database, Dr. Berman and his colleagues have authored over 65 manuscripts dealing with risk stratification using MPI, providing much of the preliminary information regarding ischemia and outcomes that supports other studies such as the $84MM NIH-funded International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial.